Tirzepatide Side Effects: What Both Labels Say and What to Watch

    Short answer

    Tirzepatide is the active ingredient in Mounjaro, approved for type 2 diabetes, and Zepbound, approved for weight management and obstructive sleep apnea. On both FDA labels, nausea, diarrhea, vomiting, constipation, indigestion and stomach pain are among the most common side effects.

    One medicine, two brands, the same leading effects. This short guide compares the trial numbers from each label, explains how tirzepatide works, and points to the full brand guides for the serious warnings and when to get help. Both labels were revised in August 2026. It is general information, not medical advice, and Pep AI is not affiliated with Eli Lilly.

    What to Know in Four Points

    Sources: the Mounjaro and Zepbound prescribing information, both revised 08/2026.

    The Stomach Takes Most of the Hit

    Stomach side effects were reported by 37% to 44% of adults with type 2 diabetes on Mounjaro and by 56% of adults on Zepbound in its weight trials. Placebo rates were 20% and 30%, so the trials and populations differ, but the pattern is the same.

    Step-Ups Are the Peak Period

    Both labels say most nausea, vomiting and diarrhea happened during dose escalation and decreased over time, so some people notice the first weeks after a new dose more than the rest. Your prescriber can tell you what to expect at each step.

    Most People Stayed on Treatment

    Between 3.0% and 6.6% of people on Mounjaro and between 1.9% and 4.3% on Zepbound stopped because of stomach effects. Placebo rates were 0.4% and 0.5%.

    Serious Warnings Are Shared

    Both labels carry a boxed warning about thyroid C-cell tumors seen in rats. They also list pancreatitis, gallbladder disease, kidney injury from fluid loss and serious allergic reactions.

    Mounjaro vs Zepbound: Trial Rates Side by Side

    Each range runs across the doses studied on that label, next to the placebo rate from the same trials. Mounjaro's Table 1 lists effects reported by at least 5% of people; Zepbound's lists effects reported by at least 2%, so some rows appear only in the label text or not at all. Rates from different trials cannot be directly compared.

    Side effectMounjaroMounjaro placeboZepboundZepbound placebo
    Nausea12% to 18%4%25% to 29%8%
    Diarrhea12% to 17%9%19% to 23%8%
    Vomiting5% to 9%2%8% to 13%2%
    Constipation6% to 7%1%11% to 17%5%
    Indigestion5% to 8%3%9% to 10%4%
    Stomach pain5% to 6%4%9% to 10%5%
    Decreased appetite5% to 11%1%Not in tableNot in table
    Injection site reactions3.2% (label text)0.4%6% to 8%2%
    Burping2.5% to 3.3% (label text)0.4%4% to 5%1%
    FatigueNot in tableNot in table5% to 7%3%
    Hair lossPostmarketing reports onlyNo rate4% to 5%1%
    DizzinessNot in tableNot in table4% to 5%2%
    Any stomach effect37% to 44%20%56%30%
    Stopped for stomach effects3.0% to 6.6%0.4%1.9% to 4.3%0.5%

    Nausea

    Nausea was reported by 12% to 18% of adults on Mounjaro versus 4% on placebo. On Zepbound, it was reported by 25% to 29% versus 8% on placebo.

    Diarrhea and Vomiting

    Diarrhea was reported by 12% to 17% on Mounjaro and 19% to 23% on Zepbound. Vomiting was reported by 5% to 9% on Mounjaro and 8% to 13% on Zepbound.

    Constipation and Indigestion

    Constipation was reported by 6% to 7% on Mounjaro and 11% to 17% on Zepbound. Indigestion was reported by 5% to 8% and 9% to 10%, respectively.

    Effects in Only One Table

    Decreased appetite appears in the Mounjaro table at 5% to 11%. The Zepbound table, which uses a lower 2% cut-off, adds injection site reactions, fatigue, hair loss, dizziness and burping, each above placebo. The Mounjaro label reports injection site reactions (3.2%) and burping (2.5% to 3.3%) in its text instead, and lists hair loss only among postmarketing reports.

    Why the Numbers Differ

    The Mounjaro trials enrolled adults with type 2 diabetes, while the Zepbound trials enrolled adults with obesity or overweight. The labels say rates from different trials cannot be directly compared, so treat this table as context rather than a ranking.

    Serious Risks Both Labels Share

    Both labels carry a boxed warning about thyroid C-cell tumors seen in rats, and both warn about pancreatitis, gallbladder disease, kidney injury from fluid loss, serious allergic reactions and aspiration during anesthesia. Both also advise switching from birth control pills to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase, so talk to your prescriber about which method is right for you. The full warnings and trial figures for each brand are in Mounjaro side effects and Zepbound side effects.

    When to Call Your Prescriber or 911

    Swelling of the face, lips, tongue or throat, trouble breathing, fainting, or severe stomach pain that does not go away need emergency help, and severe or persistent vomiting, diarrhea or nausea, signs of dehydration or low blood sugar are reasons to contact your prescriber. Also call your prescriber right away about signs of gallbladder problems: pain in your upper stomach, fever, yellowing of your skin or eyes, or clay-colored stools. Each brand's full list is in Mounjaro side effects and Zepbound side effects.

    This is not a complete list and it is not medical advice: if something feels wrong, call.

    How Tirzepatide Works and Why It Upsets the Stomach

    Every point here comes from the labels.

    It Acts on Two Hormone Receptors

    The labels describe tirzepatide as acting on both the GIP and GLP-1 receptors. That dual action is what sets it apart from semaglutide, which acts on GLP-1 receptors only.

    Slower Digestion

    Both labels state that tirzepatide delays gastric emptying. Food that stays in the stomach longer is linked with fullness, nausea and indigestion.

    Each Dose Lasts Most of a Week

    The labels give an elimination half-life of about 5 days, and about 5 to 6 days in people with obesity. Because each weekly dose lasts for days, some people notice their symptoms follow a weekly pattern. The tirzepatide half-life calculator shows what that looks like.

    Brand-Specific Guides

    For the full diabetes trial data, read Mounjaro side effects. For the weight management and sleep apnea data, read Zepbound side effects.

    From the makers of this guide

    Keep Track of Your Own Pattern

    Pep AI lets you rate symptoms such as nausea, constipation, headache, fatigue and injection-site pain for severity each day, from a built-in list of GLP-1 symptoms grouped by body area, plus your own. A daily check-in records mood, energy and sleep quality as well. On the Dose tab, your side-effect trend sits next to your estimated level chart and above your dose history, so you can compare them.

    1. 01

      Rate Symptoms by Severity

      Pick from the built-in list or add your own, and rate how strong each one was that day.

    2. 02

      Side-effect trend on the Dose tab

      Your symptom trend over recent days, on the same tab as your Mounjaro or Zepbound doses.

    3. 03

      Estimated level chart

      An estimate from your logged doses and the label half-life, not a lab value.

    Download on the App StoreGet it on Google Play

    Bring a Clear Record to Each Appointment

    Pep AI exports a PDF report of your full history, including your doses and weight. A few seconds a day keeps your log complete, so the report is current when the next visit comes. For the symptoms worth raising with your prescriber, see Mounjaro side effects or Zepbound side effects.

    Key takeaways

    • Stomach side effects were reported by 37% to 44% of adults on Mounjaro and 56% on Zepbound, versus 20% and 30% on placebo.
    • Both labels say most nausea, vomiting and diarrhea happened during dose escalation and decreased over time.
    • 3.0% to 6.6% stopped Mounjaro and 1.9% to 4.3% stopped Zepbound because of stomach effects, versus 0.4% and 0.5% on placebo.
    • Both labels carry the boxed thyroid C-cell tumor warning; the brand guides hold the full warnings and call lists.
    • The two labels' trials enrolled different people, so their rates cannot be directly compared.

    Bring your own pattern, not just the label's.

    Pep AI logs your Mounjaro or Zepbound shots, symptoms with severity, meals and weight, and makes a PDF of your doses, injection sites and weight. Download Pep AI on iPhone or Android.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Mounjaro (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    2. Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    3. MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    This page summarizes the Mounjaro and Zepbound (both revised 08/2026) prescribing information for tirzepatide. It is general information, not medical advice, and does not replace your prescriber or pharmacist. Rates from different trials cannot be directly compared. Pep AI is not affiliated with or endorsed by Eli Lilly and Company. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026